User:Mr. Ibrahem/Pemigatinib

Pemigatinib, sold under the brand name Pemazyre, is a medication used to treat bile duct cancer (cholangiocarcinoma). It is used in cases which are FGFR2 positive and have failed other treatments. It is taken by mouth.

Common side effects include high or low phosphate, hair loss, diarrhea, tiredness, taste disturbances, inflammation of the mouth, dry eyes, rash, and kidney problems. Other side effects may include eye problems. Use in pregnancy may harm the baby. It is a kinase inhibitor and works by blocking fibroblast growth factor receptors.

Pemigatinib was approved for medical use in the United States in 2020. It received conditional approval in Europe in 2021. In the United States it costs about 17,800 USD every three weeks. In the United Kingdom this amount costs the NHS about £7200.